Dr. Ronald Levy to contribute deep expertise on cancer targets and experience in personalized anticancer drug development, as a scientific advisor to the company
CAMBRIDGE, Mass., Sept. 19, 2016 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), based in Cambridge, Massachusetts, today announced the addition of Stanford University scientist and renowned lymphoma specialist Ronald Levy, to its Scientific Advisory Board.
"Dr. Levy is widely recognized expert in the biology and treatment of lymphoma. He will be an invaluable contributor to Dragonfly's work developing immunotherapies that eliminate cancer," said Dragonfly's co-founder and head of MIT's Koch Institute, Dr. Tyler Jacks. "We are thrilled to have him join us as an experienced advisor and guide."
Ronald Levy is an American medical doctor and scientist at Stanford University. He specializes in lymphoma, including Non-Hodgkin's Lymphoma, Burkitt's Lymphoma and Hodgkin's Disease. His research investigates how the immune system can be harnessed to fight lymphoma. His work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma. Levy's work has been recognized with the American Cancer Society's Medal of Honor, the Karnofsky Award from the American Society of Clinical Oncology, and others. He is a member of the National Academy of Sciences and of the Institute of Medicine.
"There is virtually no one in the world who has escaped the devastating experience of a family member or friend, with cancer," said Dr. Levy. "We are in the midst of a revolution in personalized medicine, including anticancer drugs. New immunotherapies represent one of the greatest opportunities ever seen in modern medicine, and am thrilled to assist the Dragonfly team in their development of novel drugs that fight cancer."
About Dragonfly Therapeutics
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.
We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dragonfly-therapeutics-adds-leading-lymphoma-specialist-to-its-scientific-advisory-board-300328762.html
SOURCE Dragonfly Therapeutics, Inc.